# CH \$190.00 296740

# TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM350373

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

## **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
MIDCAP FINANCIAL TRUST		07/29/2015	LIMITED LIABILITY COMPANY:

# **RECEIVING PARTY DATA**

Name:	IMMUNE PHARMACEUTICALS, INC.
Street Address:	430 EAST 29TH STREET
Internal Address:	SUITE 940
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10016
Entity Type:	CORPORATION: DELAWARE
Name:	MAXIM PHARMACEUTICALS, INC.
Street Address:	8899 UNIVERSITY CENTER LANE
Internal Address:	SUITE 400
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92122
Entity Type:	CORPORATION: DELAWARE
Name:	CYTOVIA, INC.
Street Address:	6650 NANCY RIDGE DRIVE
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
Entity Type:	CORPORATION: DELAWARE

## **PROPERTY NUMBERS Total: 7**

Property Type	Number	Word Mark
Registration Number:	2967403	CEPLENE
Serial Number:	85021009	CEPLENE
Registration Number:	3252103	VONTIV
Serial Number:	85009435	CROLIBULIN
Registration Number:	3265139	EPICEPT
	•	TRADEMARK

900333359 REEL: 005593 FRAME: 0109

Property Type	Number	Word Mark
Registration Number:	1906291	LIDOPAIN
Registration Number:	3366649	LIDOPAIN

### **CORRESPONDENCE DATA**

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: lagould@mintz.com

Correspondent Name: MINTZ LEVIN


Address Line 1: One Financial Center
Address Line 2: Stephanie Leopold

Address Line 4: Boston, MASSACHUSETTS 02111

ATTORNEY DOCKET NUMBER:	46981-001
NAME OF SUBMITTER:	Leslie Gould
SIGNATURE:	/lesliegould/
DATE SIGNED:	08/05/2015

### **Total Attachments: 43**

source=MidCapImmuneRelease1#page1.tif source=MidCapImmuneRelease1#page2.tif source=MidCapImmuneRelease1#page3.tif source=MidCapImmuneRelease1#page4.tif source=MidCapImmuneRelease1#page5.tif source=MidCapImmuneRelease1#page6.tif source=MidCapImmuneRelease1#page7.tif source=MidCapImmuneRelease1#page8.tif source=MidCapImmuneRelease1#page9.tif source=MidCapImmuneRelease1#page10.tif source=MidCapImmuneRelease1#page11.tif source=MidCapImmuneRelease1#page12.tif source=MidCapImmuneRelease1#page13.tif source=MidCapImmuneRelease1#page14.tif source=MidCapImmuneRelease1#page15.tif source=MidCapImmuneRelease1#page16.tif source=MidCapImmuneRelease1#page17.tif source=MidCapImmuneRelease1#page18.tif source=MidCapImmuneRelease1#page19.tif source=MidCapImmuneRelease1#page20.tif source=MidCapImmuneRelease1#page21.tif source=MidCapImmuneRelease1#page22.tif source=MidCapImmuneRelease1#page23.tif source=MidCapImmuneRelease1#page24.tif source=MidCapImmuneRelease1#page25.tif source=MidCapImmuneRelease1#page26.tif source=MidCapImmuneRelease1#page27.tif



### RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of July 29, 2015 ("Effective Date") by MIDCAP FINANCIAL TRUST, in its capacity as Administrative Agent ("Grantee"), in favor of IMMUNE PHARMACEUTICALS, INC. (f/k/a EpiCept Corporation), MAXIM PHARMACEUTICALS, INC. and CYTOVIA, INC., (each a "Grantor" and, collectively, the "Grantors").

WHEREAS, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement, dated as of May 27, 2011 (the "May 2011 Agreement"), Grantors assigned, transferred and conveyed to Grantee, and granted to Grantee, a security interest in all of Grantors' right, title and interest in and to the Intellectual Property Collateral (as defined in the May 2011 Agreement, the "Intellectual Property Collateral");

WHEREAS, the May 2011 Security Agreement was recorded with the United States Patent and Trademark Office on May 31, 2011 at Reel 026360, Frame 0023 and at Reel 004551, Frame 0029. A corrective filing was recorded with the United States Patent and Trademark Office on October 27, 2011 at Reel 4649, Frame 0833.

WHEREAS, Grantee has consented to the release of the lien on all of the Intellectual Property Collateral, including but not limited to the patents and trademarks listed on <u>Schedule 1</u> hereto (collectively, the "<u>Released IP Collateral</u>");

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby covenants and agrees as follows:

- 1. Grantee's mortgage, pledge, and hypothecation and lien on and security interest in the Released IP Collateral is hereby terminated and released.
- 2. To the extent Grantee retains any such interest, Grantee hereby assigns, transfers and conveys to Grantors, all of Grantee's right, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Released IP Collateral. Such assignment, transfer and conveyance by Grantee is made without any representation or warranty (express or implied) by Grantee.
- 3. Grantee hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release, all at the expense of Grantors. Grantee authorizes Grantors (or their agents) to file such documentation as is necessary to effect the releases of the Intellectual Property Collateral granted hereunder.
- 4. This Release may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original. Delivery of an executed counterpart of a signature page to this Release by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Release.

[the remainder of this page intentionally left blank]

IN WITNESS WHEREOF, Grantee has caused this Release to be executed by its duly authorized representative as of the Effective Date.

## MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,

its investment manager

By: Apollo Capital Management GP, LLC,

its general partner

By: \_\_\_\_\_\_\_(SEAL)

Name: Maurice Amsellem Title: Authorized Signatory

# Schedule 1

[See attached]

Schedule 1 to Release of Security Interest in Intellectual Property

# EXHIBIT A

Copyrights

None.

# EXHIBIT B

**Patents** 

[See Attached]

EpiCept Patent Portfolio (May 2011) SKGF. Ref.	Title	Country	Patent No./Appl. No.	Issue Date/File Date	<u>Status</u>
1735.0010001	Dipeptide Caspase Inhibitors and the Use Thereof	USA	6,153,591 09/270,735	11/28/2000 3/16/1999	Granted.
1735,0030001	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,248,904 09/357,952	6/19/2001 7/21/1999	Granted.
1735.0030003	Novel Fluorescence Dyes and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases, Peptidases, Proteases, and Other Enzymes and the Use Thereof	USA	6,984,718 10/138,375	1/10/2006 5/6/2002	Granted.
1735.0280002	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,184,210 09/270,736	2/6/2001 3/16/1999	Granted.
1735.0280003	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,596,693 09/653,279	7/22/2003 8/31/2000	Granted.
1735.0280004	Dipeptide Apoptosis Inhibitors and the Use Thereof	USA	6,949,516 10/429,095	9/27/2005 5/5/2003	Granted.
1735.028AU01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Australia	741203 97930/98	3/7/2002 10/9/1998	Granted.
1735.028CA01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Canada	2,306,692 2,306,692	9/21/2010 10/9/1998	Granted.
1735.028CN01	Dipeptide Apoptosis Inhibitors and the Use Thereof	China	ZL98810022.3 98810022.3	2/18/2004 10/9/1998	Granted.
1735.028EP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	EPC	98952166.1	10/9/1998	10/9/1998 Pending.
1735.028JP01	Dipeptide Apoptosis Inhibitors and the Use Thereof	Japan	4439111 2000-515426	1/15/2010 10/9/1998	Granted.
1735.028KR01	Dipeptide Apoptosis Inhibitors and the Use Thereof	South Korea	10-0580333 10-2000-7003882	5/9/2006 10/9/1998	Granted.
1735.0290002	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	USA	6,342,611 09/168,888	1/29/2002 10/9/1998	Granted.

Granted.	2/25/2004	1230232	Germany	Substituted 4H-Chromene and Analogs as Activators of	1735.041DE02
Granted.	3/29/2011 11/3/2000	1/16/8444 1/16/8444	Canada	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.041CA02
Granted.	10/6/2005 11/3/2000	12/31/4040 14619/01	Australia	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.041AU02
Granted.	7,507,762 3/24/2009 3/7/2005	7,507,762 11/072,499	USA	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0410003
Granted.	3 6/14/2005 11/6/2000	6,906,203 09/705,840	USA	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0410002
Granted.	12/17/2002 8/28/2000	6,495,522 09/649,810	USA	Substituted Alpha-Hydroxy Acid Caspase Inhibitors and the Use Thereof	1735.0400002
Granted.	4/6/2004 11/14/2001	6,716,818 09/987,417	USA	Caspase Inhibitors and the Use Thereof	1735.0350003
Granted.	3/12/2002 4/7/2000	6,355,618 09/545,565	USA	Caspase Inhibitors and the Use Thereof	1735.0350002
Granted.	9/16/2003 3/16/2000	6,620,782 09/527,225	USA	Substituted 2-Aminobenzamide Caspase Inhibitors and the Use Thereof	1735.0330002
Granted.	9/2/2003 2/6/2002	6,613,762 10/066,805	USA	Gambogic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	1735.0320005
Granted.	10/8/2002 2/1/2000	6,462,041 09/495,120	USA	Gambogic Acid, Analogs and Derivatives as Activators of Caspases and Inducers of Apoptosis	1735.0320003
Granted.	9/18/2007 4/22/2004	7,270,801 10/829,381	USA	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	1735.0290006
Granted.	7/6/2004 9/7/2001	6,759,207 09/947,387	USA	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	1735.0290005
Granted.	1/1/2002 3/8/2000	6,335,429 09/521,650	USA	Novel Fluorogenic or Fluorescent Reporter Molecules and Their Applications for Whole-Cell Fluorescence Screening Assays for Caspases and Other Enzymes and the Use Thereof	1735.0290004

Granted.	4/6/2004 5/10/2002	6,716,859 10/141,769	USA	Substituted N'-(Arylcarbonyl)-benzhydrazides, N'-Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0560001
Granted.	8/14/2007 10/16/2003	7,256,219 10/471,720	USA	Multifluoro-substituted Chalcones and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0540001
Granted.	6/5/2007 11/10/2003	7,226,927 10/704,448	USA	Substituted 2-Aryl-4-arylaminopyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0520002
Granted.	4/6/2004 12/12/2001	6,716,851 10/012,444	USA	Substituted 2-Aryl-4-arylaminopyrimidine and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0520001
Granted.	6/8/2004 11/19/2002	6,747,052 10/298,946	USA	Substituted Indole-2-carboxylic Acid Benzylidenehydrazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0500002
Granted.	12/7/2004 8/2/2001	6,828,091 09/920,332	USA	Method of Identifying Immunosuppressive Agents	1735.0470001
Granted.	3/1/2005 4/18/2001	6,861,419 09/836,548	USA	Substituted 1,4-Thiazepene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0450001
Granted.	9/21/2004 1/26/2001	6,794,397 09/769,420	USA	Substituted Nicotinamide and Analogs as Activators of Caspases and Apoptosis and the Use Thereof	1735.0440001
Granted.	5/20/2003 10/11/2000	6,566,338 09/685,689	ent USA	1735.0420002 Caspase Inhibitors for the Treatment and Prevent USA Chemotherapy and Radiation Therapy Induced Cell Death	1735.0420002
Granted.	2/25/2004 11/3/2000	1230232 976912.6	Italy	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0411T02
Granted.	2/25/2004 11/3/2000	1230232 976912.6	Great Britain 1230232 976912.6	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.041GB02
Granted.	2/25/2004 11/3/2000	1230232 976912.6	France	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.041FR02
Granted.	2/25/2004 11/3/2000	4/3/5268 9/9/4574	Spain	Substituted 4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.041ES02
	11/3/2000	976912.6		Caspases and Inducers of Apoptosis and the Use Thereof	

Granted.	5/9/2006 6/10/2002	7,041,685 10/164,705	USA	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0640001
Granted.	9/24/2010 5/16/2002	4593880 2002-589478	Japan	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063JP01
Granted.	12/2/2009 5/16/2002	1/12/5713 7/12/9406	Italy	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063 T01
Granted.	12/2/2009 5/16/2002	1392683 2741704.7	United Kingdom	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063GB01
Granted.	12/2/2009 5/16/2002	1392683 2741704.7	France	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063FR01
Granted.	12/2/2009 5/16/2002	1392683 2741704.7	Spain	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063ES01
Granted.	12/2/2009 5/16/2002	1392683 7/12/9406	EPC	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063EP01
Granted.	12/2/2009 5/16/2002	1392683 7/12/9406	Germany	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063DE01
Granted.	12/2/2009 5/16/2002	2812067.1 3/5/9599	China	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063CN01
Pending. Allowed. Final fees to be paid by 05/22/2011.	05/16/2002	2,447,010	Canada	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063CA01
5/16/2002 Pending.	5/16/2	2009200374	Australia	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.063AU11
Granted.	7,053,117 5/30/2006 5/16/2002	7,053; 10/146,138	USA	Substituted 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis	1735.0630001
Granted.	9/21/2004 6/3/2002	6,794,400 10/158,827	USA	4-Substituted-1-(arylmethylidene)thiosemicarbazide,4-substituted-1-(arylcarbonyl)thiosemicarbazide and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0600001
Granted.	7/11/2006 4/5/2004	7,074,813 10/816,893	USA	Substituted N'-(Arylcarbonyl)-benzhydrazides, N'- Benzylidenehydrazides and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0560002

Granted.	09102/2010	2003267977	Australia	Derivatives of Gambogic Acid and Analogs as	1735.078AU02
2/13/2007 Granted. 710112003	2/1 710:	7,176,234 10/609,670	USA	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Aoontosis	1735.0780002
9 Granted. 11/16/2004	05105/2009 11/1	7,528,164 10/514,427	USA	Substituted 4-Aryl-4H-pyrrolo[2,3-h ]chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0770001
Granted.	7,476,741 1/13/2009 11/16/2004	7,476 10/514,426	USA	Substituted 4H-Chromenes, 2H-Chromenes, Chromans and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0750001
Granted.	6/26/2007 11/16/2004	7,235,674 10/989,057	USA	Substituted Courmarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0660002
Granted.	3/21/2006 5/16/2002	7,015,328 10/146,136	USA	Substituted Courmarins and Quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0660001
Granted.	2/22/2005 5/16/2002	6,858,607 10/146,139	USA	7,8-Fused 4H-Chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0650001
Granted.	2/23/2005 6/10/2002	2003/9309 2003/9309	South Africa	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.064ZA01
6/10/2002 Pending.	6/1	2753336.3	EPC	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.064EP01
6/10/2002 Pending.	6/1	2813660.8	China	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.064CN01
6/10/2002 Pending.	6/1	2,449,544	Canada	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.064CA01
Granted.	6/14/2007 6/10/2002	2002313633 2002313633	Australia	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.064AU01
Granted.	10/14/2008 3/8/2005	7,435,750 11/074,077	USA	Substituted 3-Aryl-5-aryl-{1,2,4}-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	1735.0640002

	Activators of Caspases and Inducers of Apoptosis		2003267977	710112003	
1735.078CN02	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	China	3815628.8 3815628.8	09108/2010 Gra 710112003	Granted.
1735.0810001	Substituted I-Benzoyl-3-cyano-pyrrolo[ 1 ,2-a ]quinolines and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,135,480 101,733,229	11/14/2006 Granted 12/12/2003	inted.
1735,0820001	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,144,876 101,737,865	12105/2006 Gra 12/18/2003	Granted.
1735.0820002	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,317,029 111,593,030	01108/2008 Gra 11106/2006	Granted.
1735.082AUOI	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Australia	2003303373 2003303373	5/27/2010 Granted 12/18/2003	inted.
1735.082CNOI	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	2.0038E+11 2.0038E+11	1/30/2008 Granted 12/18/2003	inted.
1735.082EPOI	3,5-Disubstituted-[1,2,4]-oxadiazoles and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	EPC	3808469.5	12118/2003 Pen paic dea	Pending. Renewal fee not paid for 12/3112010; deadline 06/30/2011.
1735.0840002	Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays	USA	7,592,143 10/826,909	9/22/2009 Granted 4/19/2004	inted.
1735.088001	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	USA	7,504,382 10/839,753	3/17/2009 Granted 05106/2004	nted.
1735.088CN06	Protease Inhibitors for Corona virus and Sars-Co V and the Use Thereof	China	2.0048E+11 2.0048E+11	07102/2008 Gra 05104/2004	Granted.
1735.0940001	Derivatives of Gambogic Acid and Analogs as Activators of Caspases and Inducers of Apoptosis	USA	7,622,497 10/580,263	11/24/2009 Granted 5/25/2006	inted.
1735.1040001	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	USA	11/822,535	07106/2007 Pen Fee	Pending. Allowed. Issue Fee due 05/23/2011.
1735.104AUOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and	Australia	2007271743	07106/2007 Pen	Pending.

	the Use Thereof				
1735 .104CAO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Canada	2,656,706	07106/2007	Pending.
1735.104CNOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	China	2.0078E+11	07106/2007	Pending.
1735.104EPOI	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	EPC	7810283.7	07106/2007	Pending.
1735 .104JPO 1	Substituted 4-Aryl-chromene as Activator of Caspases and Inducer of Apoptosis and as Antivascular Agent and the Use Thereof	Japan	2009-518401	07106/2007	Pending.
1735.1050002	3-Aryl-6-aryl- 7 H-[ 1 ,2,4 ]triazolo[3 ,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	111,879,517	07118/2007	Pending.
1735.105CA02	3-Aryl-6-aryl- 7 H-[ 1 ,2,4 ]triazolo[3 ,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Canada	2,657,931	07118/2007	Pending.
1735.105CN02	3-Aryl-6-aryl- 7 H-[ 1 ,2,4 ]triazolo[3 ,4-b][1,3,4]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	China	ТВА	07118/2007	Pending.
1735.105EP02	3-Aryl-6-aryl- 7 H-[ 1 ,2,4 ]triazolo[3 ,4-b] [1,3,4 ]thiadiazines and Analogs as Activators of Caspases and Inducers of Aoontosis and the Use Thereof	EPC	7796912.9	07118/2007	Pending.
1735.105JP02	3-Aryl-6-aryl- 7 H-[ 1,2,4 ]triazolo[3,4-b] [1,3,4 ]thiadiazines and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	Japan	2009-520810	07118/2007	Pending.
1735.1080001	3-aryl-6-aryl-[ 1,2,4 ]triazolo[3,4-b][ 1,3,4]thiadiazoles and Related Compounds as Activators of Caspases and Inducers of Apoptosis and the Use Thereof	USA	7,732,468 111,984,296	06108/2010 11/15/2007	Granted.

Patent Status Report by Client
Client: MAXIM

**EpiCept Corporation** 

Tuesday, April 26, 2011

Client Code/SubCase	Case Type	ClientReferent Pat Number	r App Date	Next Action(s)
MAXIM.010CP1/	CIP	Issued 07/843052		2-Mar-92
Country:	United States of America	5348739	20-Sep-94	
Attorneys:	MKD - Billing			
Title:	COMBINED ANTI-TUMOR THERAPY WITH INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	D HISTAMINE, ANALOGS THERE(	)F OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VAT/	EPC	Issued	90914257.2	19-Sep-90
Country:	Austria	493468	17-Apr-96	
Attorneys:	MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	ID HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VAU/	ORD	Issued 64191/90		19-Sep-90
Country:	Australia	640954	25-Jan-94	
Attorneys:	amh - IPS; MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLETIKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	THE ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VBE/	EPC	Issued	90914257.2	19-Sep-90
Country:	Belgium	493468	17-Apr-96	
Attorneys:	MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	AD HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VCA/	ORD	Issued	2066728	19-Sep-90
Country:	Canada	2066728	25-Dec-01	
Attorneys:	amh - IPS; MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	VD HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VCH/	EPC	Issued	90914257.2	19-Sep-90
Country:	Switzerland	493468	17-Apr-96	
Attorneys:	MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	VD HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VDE/	EPC	Issued	90914257.2	19-Sep-90
Country:	Germany	493468	17-Apr-96	
Attorneys:	MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	VD HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VDK/	EPC	Issued	90914257.2	19-Sep-90
Country:	Denmark	493468	17-Apr-96	
Attorneys:	MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	ID HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				
MAXIM.010VEP/	ORD	Issued	90914257.2	19-Sep-90
Country:	European Patent Convention	493468	17-Apr-96	
Attorneys:	amh - IPS; MKD - Billing			
Title:	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	ID HISTAMINE, ANALOGS THERE	OF OR H2-	
RECEPTOR AGONISTS				

Due Date(s)

	17-Apr-96	493468	Sweden	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VSE/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	Netherlands	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VNL/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	Luxembourg	Country:
19 <b>-</b> Sep-90	90914257.2	Issued	EPC	MAXIM.010VLU/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	Liechtenstein	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VLI/
			IED)	AND THE METASTASES OF (CONTINUED)
	IOR GROWTH	EM, AND USE THEREOF FOR INHIBITING TUN	A PHARMACEUTICAL PREPARATION OR SYSTEM, AND USE THEREOF FOR INHIBITING TUMOR GROWTH	Tide:
			amh - IPS; MKD - Billing	Attorneys:
	11-Feb-99	195392	Korea, Republic of	Country:
19-Mar-92	<b>∞</b>	Issued 92-700628	ORD	MAXIM.010VKR/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Tide:
			amh - IPS; MKD - Billing	Attorneys:
	30-Oct-98	2845622	Japan	Country:
19-Sep-90	990	Issued 513349/1990	ORD	MAXIM.010VJP/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Tide:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	Italy	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VIT/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	United Kingdom	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VGB/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Tide:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	France	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VFR/
				RECEPTOR AGONISTS
	EREOF OR H2-	ERLEUKIN-2 AND HISTAMINE, ANALOGS THI	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
			MKD - Billing	Attorneys:
	17-Apr-96	493468	Spain	Country:
19-Sep-90	90914257.2	Issued	EPC	MAXIM.010VES/

		8-Apr-14	11.5 M/Fee Due	CTS - Working; MKD - Billing	Attorneys:
	8-Apr-14	8-Oct-02 Tax 11.5	6462067	United States of America	Country:
8-Oct-13	6-Nov-00 LC re 11.5 M/Fee Due		Issued 09/707343	CON	MAXIM.066C1/
		DAMAGE		TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE-MEDIATED CELLULAR	Title:
		5-Jun-13	11 1/2 YR M/FE	CTS - Working; MKD - Billing	Attorneys:
	5-Dec-12	5-Jun-01 Tax 11.5	6242473	United States of America	Country:
5-Jun-12	8-Jan-99 11 1/2 YR LC RE M/FEE DUE		Issued 09/227455	ORD	MAXIM.066A/
				SYNERGISTIC TUMORCIDAL RESPONSE INDUCED BY HISTAMINE	Title:
		24-Dec-14	11.5 M/Fee Grad	MKD - Billing	Attorneys:
	24-Jun-14	24-Dec-02 11.5 M/Fee Due	6498181	United States of America	Country:
24-Dec-13	6-Jan-99 LC re 11.5 M/Fee Due		Issued 09/226226	ORD	MAXIM.058A/
				ADMINISTRATION OF HISTAMINE FOR THERAPEUTIC PURPOSES	Title:
		24-Apr-13	11 1/2 YR M/FE	MKD - Billing	Attorneys:
	24-Oct-12	24-Apr-01 Tax 11.5	6221893	United States of America	Country:
24-Apr-12	16-Dec-96 11 1/2 YR LC RE M/FEE DUE		Issued 08/767338	CIP	MAXIM.049CP1/
					CORRESPONDING RECEPTOR ACTIVITY
				CONTAINING INTERFERON-A AND HISTAMINE, SEROTONIN, AMINES OR SUBSTANCES WITH	CONTAINING INTERFERON-A AND HIST!
			CELLS), SAID PREPARATION	PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK CELLS), SAID PREPARATION	Title:
				amh - IPS; MKD - Billing	Attorneys:
		9-Aug-05	2136952	Canada	Country:
	3-Jun-93	2136952	Issued	ORD	MAXIM.031QCA/
				METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE	Title:
		23-Oct-13	11 1/2 YR M/FE	MKD - Billing	Attorneys:
	23-Apr-13	23-Oct-01 Tax 11.5	6305380	United States of America	Country:
23-Oct-12	19-May-00 11 1/2 YR LC RE M/FEE DUE		Issued 09/574874	CON	MAXIM.031C3/
				METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE	Tide:
		5-Dec-12	11 1/2 YR M/FE	MKD - Billing	Attorneys:
	5-Jun-12	5-Dec-00 Tax 11.5	6155266	United States of America	Country:
5-Dec-11	21-Dec-99 11 1/2 YR LC RE M/FEE DUE		Issued 09/465432	CON	MAXIM.031C2/
					CONTAINING INTERFERON-ALPHA
			CELLS), SAID PREPARATION	PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATIO	Tide:
				MKD - Billing	Attorneys:
		17-Mar-98	5728378	United States of America	Country:
	8-May-95		Issued 08/374787	ORD	MAXIM.031APC/
				NHIBITOR	HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR
		23-Apr-14	11.5 M/Fee Grad	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN N 11.5 M/Fee Grav	Tide:
		23-Oct-13	11.5 M/Fee Due	MKD - Billing	Attorneys:
	23-Oct-13	23-Apr-02 Tax 11.5	6375946	United States of America	Country:
23-Apr-13	1-Mar-00 LC re 11.5 M/Fee Due		Issued 09/516641	CON	MAXIM.026C2/
					PEROXIDE SCAVENGER OR INHIBITOR
		YDROGEN		ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN NK CELL ACTIVATOR & A H	Title:
		6-Jun-12		MKD - Billing	Attorneys:
	6-Dec-11	6-Jun-00 Tax 11.5	6071509	United States of America	Country:
6-Jun-11	22-Jul-96 11 1/2 YR L/C		Issued 08/681108	CON	MAXIM.026C1/
					RECEPTOR AGONISTS
		F OR H2-	STAMINE, ANALOGS THEREO!	ANTI-TUMOR PREPARATION COMPRISING INTERLEUKIN-2 AND HISTAMINE, ANALOGS THEREOF OR H2-	Title:
				MKD - Billing	Attorneys:

MARGONVI  MICROPANNI  DIV.  CTS Working, MCD Billing  TREADMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE. MEDITED CHLLULAR DAVA MARGONYZ.  DIV.  CTS Working, MCD Billing  TREADMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE. MEDITED CHLLULAR DAVA MARGONY.  DIV.  D	20-Dec-99			China (Poorlate Poorlatic)	Country:
MANAMERY META-ALMAN MANAMERY META-ALMAN META-ALMAN MANAMERY META-BIT MANAMERY META-B	3	99814906.3	Issued	URU	MAXIM.067VCN/
NEADMANN AND PREVENTION OF REACTIVE DAY OF R			•	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
MANUAL NAME				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
MANUAL ADJACANICA DIPLOMON DE BEACHIVE ON VICEN ME CAPITAL   DIV		2-Jul-08	1140857	Switzerland	Country:
MANY   DIV	20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VCH/
INCAMENT NO.DECTION OF REACTIVE DAYAGEM READED IT 15 MFee form   February				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
INCLANDENT AND PREVENTINO OF REACTIVE DAYAGEA METADOLITE AND GRAW   DIV   DI				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
INCADENT ADD PROPRIED OF REACTIVE DAYAGEN MEASURED ITS MORE form   MACE		14-Sep-10	2356871	Canada	Country:
READ MINE AND PREVENTION OF REACTIVE DAY GREEN BELDAUGE From   SOUTH	20-Dec-99	2356871	Issued	ORD	MAXIM.067VCA/
REALMENT AND PREVENTION OF REACTIVE DAY CREAM IN ADMIN   SOUTH				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
IREATMENT AND PERVENTION OF REACTIVE DAY GEN METADOLLIS Mires (Fast 16081896)   Estate 10981896   Es				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
IREATMENT AND PREVENTION OF REACTIVE DAY CLEAR METABOLITS More Grav   More of the Clear		2-Jul-08		Belgium	Country:
MANNY   DIV   DI	20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VBE/
MADAYI   DIV   D				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
MANYII   DPU   D				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
AGAPULI   DIV		6-Nov-03	763523	Australia	Country:
REALMENT AND FRENCHION OF REACTIVE DAYGEN MELABOLL ILS Mire & Grav.   RADIO-11.5 Mire & Due   United States of America   CTS- Working, MED - Billing   CTS- Working, MED - Billing   CTS- Working, MED - Billing   T.5 Mire & Grav.   R-Jun-02 IL5 Mire & Due	20-Dec-99			ORD	MAXIM.067VAU/
INCLAIMANN INAD PREVENTION OF REACTIVE DXYGEN METABOLI ILS M/Fee Grav				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
ADDITION OF REACTIVE DAY GEN METABOLI ILS Mifee Grav   School   Subset of America   Subset of Subset of America   Subset of Subset of America   Subset of Subset of Subset of America   Subset of				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
RICAL MENN IAND PREVENTION OF REACTIVE DAY GEN METABOLI ILS M/Fee Grav   12.4m-01 LC re 11.5 M/Fee Due   12.4m-01 LC re 11.5 M/Fee Grav   12.4m-01 LC re 11.5 M/Fee Due   12.4m-01 LC re 11.5 M/Fee Grav   12.4m-01 LC re 12.5 M/Fee Due   12.4m-01 LC re 12.5 M/Fee Due   12.4m-01 Tax 7.5   12.4m-01 Tax 7		2-Jul-08	1140857	Austria	Country:
REALDIANN   AND PREVENTION OF REACTIVE OXYGEN MEIDABULH   Solve Grav   Gord	20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VAT/
MODYJ   DIV   DIV   DIV   SECRET   SE		16-Sep-15	11.5 M/Fee Grad	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
REALIMENT AND PREVENTION OF REACTIVE DAX/GEN METABOLI ILS M/Fee Grav   12-Apr-01 LC re ILS M/Fee Due   11.5 M/Fee Grav   18-Jun-14   11.5 M/Fee Grav   18-Jun-14   11.5 M/Fee Grav   18-Jun-14   11.5 M/Fee Grav   11.5 M/Fee Grav   11.5 M/Fee Due   11.5 M/Fee Grav   11.5 M/Fee Due   11.5 M/Fee Grav   11.5 M/Fee Grav   11.5 M/Fee Due   11.5 M/Fee Grav   11.5 M/Fee Due   11.5 M/Fee Grav   11.5 M/Fee Due   11.5 M/Fee Grav   4-May-15		16-Mar-15	11.5 M/Fee Due	CTS - Working; MKD - Billing	Attorneys:
REALIMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT ILS M/Fee Grav		16-Sep-03 Tax 11.5	6620942	United States of America	Country:
REALMENT AND PREVENTION OF REACTIVE OXYGEN MEIABOLI II.5 M/Fee Grav   12-Apr-01 LC re 11.5 M/Fee Due   15 stude   6407133   18-Jun-02 11.5 M/Fee Due   17 stude States of America   6407133   18-Jun-02 11.5 M/Fee Due   18-Jun-14   18-Jun-14   11.5 M/Fee Due   18-Jun-15   11.5 M/Fee Due   18-Jun-14   11.5 M/Fee Due   18-Jun-15   11.5 M/Fee Due   18-Jun-16   11.5 M/Fee Due   11.5 M	10-Feb-03 LC re 11.5 M/Fee Due			CON	MAXIM.067C2/
READMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITILS Mfee Grav   12-Apr-01 LC re 11.5 Mfee Due   12-Apr-01 LC re 11.5 Mfe		4-Mar-15	11.5 M/Fee Grad	SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
REALMENT AND PREVENTION OF REACTIVE OXYGEN METABOLI ILS M/ree Grav   8-Oct-14		4-Sep-14	11.5 M/Fee Due	CTS - Working; MKD - Billing	Attorneys:
REALMEN AND PREVENTION OF REACTIVE OXYGEN METABOLI II.5 M/ree Grav   Schef4		4-Mar-03 Tax 11.5	6528654	United States of America	Country:
IREAIMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT II.5 M/Fee Grav   S-Oct-14	9-Oct-01 LC re 11.5 M/Fee Due			CON	MAXIM.067C1/
				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
REALMENT AND PREVENTION OF REACTIVE OXYGEN METABOLI II.5 M/ree Grav   8-Oct-14   12-Apr-01 LC re 11.5 M/ree Due   12-Apr-01 LC re		11-Jun-14	11.5 M/Fee Grad	CTS - Working; MKD - Billing	Attorneys:
		11-Jun-02 11.5 M/F	6403806	United States of America	Country:
	20-Dec-99 LC re 11.5 M/Fee Due			ORD	MAXIM.067A/
			4-May-16		11.5 M/Fee Grace Period
11.5 M/Fee Due   12.4 pr. 01 LC re 11.5 M/Fee Grav   12.4 pr. 01 LC re 11.5 M/Fee Due   12.4 pr. 01 LC re 11.5 M/Fee Du			4-Nov-15		Tax 11.5
DIV   IREALIMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT 11.5 M/Fee Grav   8-Oct-14   12-Apr-01 LC re 11.5 M/Fee Due   12-Apr-0			4-Sep-15		FU LC re 11.5 M/Fee Due
TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT   11.5 M/Fee Grav   8-Oct-14   12-Apr-01 LC re   11.5 M/Fee Due		4-May-15	ÆTABOLΓ LC re 11.5 M/Fε	TREATMENT AND PREVENTION OF REACTIVE OXYGEN N	Title:
1.5 M/Fee Grav   1.5 M/Fee Grav   1.5 M/Fee Due   1.5 M/Fee		4-May-12	7.5 M/Fee Grace	CTS - Working; MKD - Billing	Attorneys:
12-Apr-01 LC re 11.5 M/Fee Due 15 M/Fee Due 16 M/Fee Due 16 M/Fee Due 16 M/Fee Due 17 M/Fee Due 18 M/Fee Due 18 Jun-02 II.5 M/Fee Due	4-No	4-May-04 Tax 7.5	6730692	United States of America	Country:
IREALMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT 11.5 M/Fee Grav  Stoned  O/O/DVI  DIV  ISSUED  O/0/833896  19-Apt-01 LC re 11.5 M/Fee Due  6407133  18-Jun-02 11.5 M/Fee Due  CTS - Working; MKD - Billing  TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE- MEDIATED CELLULAR DAMAGE	11-Jun-02 FU LC re 7.5 M/Fee Due			DIV	MAXIM.066DV2/
160DVI)  DIV  Sound  So			ÆTABOLITE- MEDIATED CELLULAR I	TREATMENT AND PREVENTION OF REACTIVE OXYGEN N	Title:
IREAIMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT 11.5 M/Fee Gra 8-Oct-14  15 M/Fee Gra 8-Oct-14  17 DIV Issued 09/833896 12-Apt-01 LC re 11.5 M/Fee Due  18 Jun-02 11.5 M/Fee Due			11.5 M/Fee Grad	CTS - Working; MKD - Billing	Attorneys:
IREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLLTIL5 M/Fee Grad 8-Oct-14  DIV Issued 09/833896		18-Jun-02 11.5 M/F	6407133	United States of America	County:
IREALIMENT AND PREVENTION OF REACTIVE OXYGEN METABOLT ILS MIFEE Grad 8-Oct-14				DIV	MAXIM.066DVI/
		8-Oct-14		TREATMENT AND PREVENTION OF REACTIVE OXYGEN N	Title:

	21-Nov-06	143570	Israel	Country:
20-Dec-99	143570	Issued	ORD	MAXIM.067VIL/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Ireland	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VIE/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	24-Apr-09	HK1040998	Hong Kong	Country:
20-Dec-99	2102715.8	Issued	ORD	MAXIM.067VHK/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Greece	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VGR/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	United Kingdom	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VGB/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	France	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VFR/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Finland	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VFI/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Spain	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VES/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	European Patent Convention	County:
20-Dec-99	99968148.9	Issued	ORD	MAXIM.067VEP/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS: CTS - Working: MKD - Billing	Attorneys
	2-Jul-08	1140857	Denmark	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VDK/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	69939027.3-08	Germany	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VDE/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Cyprus, Republic of	County:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VCY/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:

20-Dec-99	2001/4552	Issued 200	ORD	MAXIM.067VZA/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	11-Nov-05	1243166	Taiwan	Country:
23-Dec-99	88122820	Issued	ORD	MAXIM.067VTW/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Sweden	County:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VSE/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Portugal	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VPT/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	8-Dec-03	512935	New Zealand	Country:
20-Dec-99	512935	Issued	ORD	MAXIM.067VNZ/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Netherlands	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VNL/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Monaco	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VMC/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Luxembourg	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VLU/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
			Korea, Republic of	Country:
20-Dec-99	10-2001-7007847	Pending 10-	ORD	MAXIM.067VKR/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	13-Jun-08	4139082	Japan	Country:
20-Dec-99	2000-591009	Issued 200	ORD	MAXIM.067VJP/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	2-Jul-08	1140857	Italy	Country:
20-Dec-99	99968148.9	Issued	EPC	MAXIM.067VIT/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:
	13-Apr-07	205849	India	Country:
20-Dec-99	IN/PCT/2001/00601	Issued IN	ORD	MAXIM.067VIN/
			SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Title:
			amh - IPS; CTS - Working; MKD - Billing	Attorneys:

and the same	the second secon	4 4 4			
18-May-11	9-Anr-10 File Refs in All II. Applicatio	30604	Published PCT/IIS2010/030604	ORD	MAXIM 217VPC/
			23-Nov-16		11.5 M/Fee Grace Period
			23-May-16		Tax 11.5
			23-Mar-16		FULC re 11.5 M/Fee Due
			23-Nov-15		LC re 11.5 M/Fee Due
		23-N <sub>0V</sub> -12	MATURATIO 7.5 M/Fee Grace	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATIO 7.5 M/Fee Grace	Title:
		23-May-12	Tax 7.5	MKD - Billing	Attorneys:
	W/Fee Due 23-Mar-12	23-Nov-04 FU LC re 7.5 M/Fee Due	6821510	United States of America	Country:
23-Nov-11	30-May-02 LC re 7.5 M/Fee Due		Issued 10/160368	DIV	MAXIM.085DV4/
			17-May-17		11.5 M/Fee Grace Period
			17-Nov-16		Tax 11.5
			17-Sep-16		FULC re 11.5 M/Fee Due
			17-May-16		LC re 11.5 M/Fee Due
		17-May-13	MATURATIO 7.5 M/Fee Grace	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATIO 7.5 M/Fee Grace	Title:
		17-Nov-12	Tax 7.5	MKD - Billing	Attorneys:
	M/Fee Due 17-Sep-12	17-May-05 FU LC re 7.5 M/Fee Due	6893633	United States of America	Country:
17-May-12	30-May-02 LC re 7.5 M/Fee Due		Issued 10/160360	DIV	MAXIM.085DV3/
			14-Sep-16		11.5 M/Fee Grace Period
			14-Mar-16		Tax 11.5
			14-Jan-16		FULC re 11.5 M/Fee Due
			14-Sep-15		LC re 11.5 M/Fee Due
		14-Sep-12	MATURATIO 7.5 M/Fee Grace	METHODS AND COMPOSITIONS FOR PROMOTING THE MATURATIO 7.5 M/Fee Grace	Title:
		14-Mar-12	Tax 7.5	MKD - Billing	Attorneys:
	M/Fee Due 14-Jan-12	14-Sep-04 FU LC re 7.5 M/Fee Due	6790440	United States of America	Country:
14-Sep-11	30-May-02 LC re 7.5 M/Fee Due		Issued 10/160745	DIV	MAXIM.085DV1/
			N AND PROTECTION OF CYTOTOXIC	USE OF DIPHENYLIONODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC	Title:
				amh - IPS; MKD - Billing	Attorneys:
		19-May-05	779215	Australia	Country:
	14-Jul-00	200061044	Issued	ORD	MAXIM.078VAU/
				OR RELEASE INHIBITORS	OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS
		IVE	MENT OF DAMAGED TISSUE USING REACT	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE	Title:
				amh - IPS; MKD - Billing	Attorneys:
		29-Mar-04	513272	New Zealand	Country:
	7-Jan-00	513272	Issued	ORD	MAXIM.073QNZ/
				OR RELEASE INHIBITORS	OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS
		IVE	MENT OF DAMAGED TISSUE USING REACT	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE	Title:
		26-Feb-14	11 1/2 YR M/FE	MKD - Billing	Attorneys:
	26-Aug-13	26-Feb-02 Tax 11.5	6350785	United States of America	Country:
26-Feb-13	19-Jan-01 11 1/2 YR LC RE M/FEE DUE		Issued 09/765929	DIV	MAXIM.073DV1/
				OR RELEASE INHIBITORS	OXYGEN METABOLITE PRODUCTION OR RELEASE INHIBITORS
		IVE	MENT OF DAMAGED TISSUE USING REACT	METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE	Tide:
		7-Aug-13	11 1/2 YR M/FE	MKD - Billing	Attorneys:
	7-Feb-13	7-Aug-01 Tax 11.5	6270781	United States of America	Country:
7-Aug-12	8-Jan-99 11 1/2 YR LC RE M/FEE DUE		Issued 09/227801	ORD	MAXIM.073A/
				SYNTHESIS OF HISTAMINE DIHYDROCHLORIDE	Tide:
				amh - IPS; CTS - Working; MKD - Billing	Attorneys:
		27-Mar-02	2001/4552	South Africa	Country:

				'AMINE LEVELS	ELEVATION OF CIRCULATING BLOOD HISTAMINE LEVELS	Title:
		6-Jun-12	11.5 GRACE PI	11.5 G	MKD - Billing	Attorneys:
	6-Dec-11	6-Jun-00 Tax 11.5	6071942		United States of America	Country:
6-Jun-11	13-Nov-97 11 1/2 YR L/C	13-	08/969384	Issued	CIP	MAXIM.49CPCP/
				D INFECTIOUS DISEASE	METHOD FOR TREATMENT OF CANCER AND INFECTIOUS DISEASE	Title:
					MKD - Billing	Attorneys:
	21-Jun-11	21-Dec-99 <b>Tax 11.5</b>	6003516		United States of America	Country:
21-Jun-11	2-Mar-98 Tax 11.5	2-	09/033110	Issued	CON	MAXIM.31C1/
					R INHIBITOR	HYDROGEN PEROXIDE SCAVENGER OR INHIBITOR
			ACTIVATOR AND A	LER CELLS USING AN NK CELI	ENHANCED ACTIVATION OF NATURAL KILLER CELLS USING AN NK CELL ACTIVATOR AND A	Title:
		12-Jun-13	11 1/2 YR M/FE	11 1/2	MKD - Billing	Attorneys:
	12-Dec-12	12-Jun-01 Tax 11.5	6245563		United States of America	Country:
12-Jun-12	1-Mar-00 11 1/2 YR LC RE M/FEE DUE	-	09/516738	Issued	CON	MAXIM.26D1F1C1/
						SCAVENGER OR INHIBITOR
		ROXIDE	ND A HYDROGEN PER	NG AN NK CELL ACTIVATOR A	ENHANCED ACTIVATION OF NK CELLS USING AN NK CELL ACTIVATOR AND A HYDROGEN PEROXIDE	Title:
		16-May-12	11.5 GRACE PI	11.5 G	MKD - Billing	Attorneys:
	16-Nov-11	16-May-00 Tax 11.5	6063373		United States of America	Country:
16-May-11	17-Sep-97 11 1/2 YR L/C	17.	08/932406	Issued	FW	MAXIM.26D1F1/
				16-Nov-11		NP 31 Month Date FINAL / IPS
				16-Oct-11		NP 30 Month Date FINAL / IPS
				16-Oct-11		File Nat'l Phase in US? / ATTY
				9-Oct-11		NP w/\$300 Late Fee / ATTY
				2-Oct-11		NP w/\$100 Late Fee / ATTY
				18-Sep-11		NP w/out Late Fee / ATTY
				16-Sep-11		Prepare FFNP Memo / Asst
			16-Aug-11		FULC re 30 Month NP/IPS	OXYGEN RADICAL FORMATION
		16-Jul-11	Month N.	TYLHISTAMINE DIHYDR LC 30	COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDR LC 30 Month N	Title:
		18-May-11	File Resp w/Den	File Ro	amh - IPS; MKD - Billing; MZP - Working	Attorneys:
		18-May-11	IDS in US Appli	IDS in	Patent Cooperation Treaty	Country:

		ILENE B.	Attomeys:	
6-Mar-01 26-May-06			EPICEPT, INC.	301717-009004 Mexico Registered
237220	MAL TON FOR WILFRIED FISCHER KATHARINASTOEGER 2002/008828 TCS PETRA ffüBER	INTRADERMAL PENETRATION AGENTS FOR WILFRI TOPICAL LOCAL LOCAL ANESTHETICS USING PATCH	EPICEPT CORPORATION	010071-0005-009
	ILENE B. TANNEN PETER G. THURLOW	ILENE B.	Attomeys:	
II-Nov-04	March 6, 200 I		EPICEPT, INC.	301717-008004 New Zealand Registered
521470 521470	MAL FOR WILFRIED FISCHER KATHARINASTOEGER ICS PETRA ffiBER	INTRADERMAL PENETRATION AGENTS FOR WILFRI TOPICAL KATHA LOCAL ANUSTHETICS PETRA USING A PATCH	EPICEPT CORPORATION	010071-0005-008
	ILENE B. TANNEN PETER G. THURLOW	ILENE B. T	Апотеус:	
				Australia Registered
6.Moz.01			EDICEPT INC	301717-00700
2001245449 2001245449	MAL TON FOR WILFRIED FISCHER KATHARINASTOEGER TICS PETRA ffüßER 200	INTRADERMAL PENETRATION AGENTS FOR WILFRI TOPICAL KATHA LOCAL KATHA ANESTHETICS PETRA USING A	EPICEPT CORPORATION	010071-0005-007
Pat Date	ors App Date	Patent Title Inventors	Client Owner	Country Status

Jones Day Patent Report (No Actions:No 502's) April 26, 20 II

010071-0005-149		301717-117004 Philippines Filed Wait Exam	010071-0005-117		301717-056004 India Registered	010071-0005-056		301717-012004 Japan Pending	010071-0005-012
EPICEPT CORPORATION	Attomeys:	EPICEPT, INC.	EPICEPT CORPORATION	Attomeys:	EPICEPT, INC.	EPICEPT CORPORATION	Attomeys:	EPICEPT. INC.	EPICEPT CORPORATION
INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER TOPICAL KATHARINASTOEGER PV2002-3030 LOCAL KATHARINASTOEGER PV2002-3030 USING A PATCH	ILENE B. TANNEN PETER G. THURLOW	8-Mar-01	INTRADERMAL  PENETRATION  AGENTS FOR WILFRIED FISCHER  TOPICAL KATHARINASTOEGER 1-2001-00573  LOCAL PETRA ffi.BER  USING A  PATCH	ILENE B. TANNEN PETER G. THURLOW	6-Mar-01	INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER TOPICAL KATHARINASTOEGER 2002/01640 LOCAL KATHARINASTOEGER 2002/01640 ANESTHETICS PETRA ffi.BER USING A PATCH	ILENE B. TANNEN PETER G. THURLOW	6-Mar-01	PENETRATION  AGENTS FOR WILFRIED FISCHER  TOPICAL KATHARINASTOEGER 13-566701  LOCAL PETRA ffüBER  USING A  PATCH
		01			01 4-Sep-07	209506		01	

		G. THURLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:		
						Completed
					aty	Patent Cooperation Treaty
	6-Mar-01			2.4	EPICEPT, INC	301717-228004
		PCT !USO 1107060	INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER TOPICAL KATHARINASTOEGER LOCAL ANESTHETICS PETRA ffiJBER USING A PATCH	(PORATION	EPICEPT CORPORATION	010071-0005-228
		i. THURLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:		
						Registered
						Republic of Korea
28-Sep-07				2.4	EPICEPT, INC.	301717-187004
	10-0764156	10-2002-7011879	INTRADERMAL PENETRATION AGENTS FOR WILFRIED FISCHER TOPICAL KATHARINASTOEGER LOCAL ANESTHETICS PETRA ffüBER USING A PATCH	(PORATION	EPICEPT CORPORATION	010071-0005-187
		G. THURLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:		
						Registered
						Israel
	May 18,2010			2.4	EPICEPT, INC.	301717-158004
151671	151671		INTRADERMAL  PENETRATION  AGENTS FOR WILFRIED FISCHER  TOPICAL KATHARINASTOEGER  LOCAL ANESTHETICS PETRA ffißER  USING A  PATCH	(PORATION	EPICEPT CORPORATION	010071-0005-158
		G. THURLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:		
				,,,	EPICEPT, INC.	301717-149004 Czech Republic Pending

European Patent Office EP Granted	301717-227009	010071-0010-227	Filed Wait Exam	301717-158009 Israel	010071-0010-158		Pending	301717-012009 <b>Japan</b>	010071-0010-012	Registered	301717-999004 United States of America	010071-0005-999
	EPICEPT CORPORATION	EPICEPT CORPORATION	Attomeys:	EPICEPT CORPORATION	EPICEPT CORPORATION	Attomeys:		EPICEPT CORPORATION	EPICEPT CORPORATION	Attomeys:	EPICEPT CORPORATION	EPICEPT CORPORATION
KOLESNIKOV	JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A.	METHODS AND COMPOSITION S FOR S FOR TREATING PAIN OF THE MUCOUS METHODS AND ROBERT O. WILLIAMS FENGZHANG MEMBRANE	ILENE B. TANNEN PETER G. THURLOW	JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	METHODS AND COMPOSITION S FOR TREATING TREATING PAIN OF THE MUCOUS MEMBRANE	LENE B. TANNEN PETER G. THURLOW		JOHN J. KOLENG GAVRJI. W. PASTERNAK YURJ A. KOLESNIKOV	METHODS AND  COMPOSITION  S FOR  TREATING PAIN OF THE MUCOUS  METHODS AND  ROBERT O. WILLIAMS 2002-504977	ILENE B. TANNEN PETER G. THURLOW		INTRADERMAL PENETRATION AGENTS FOR TOPICAL LOCAL ANESTHETICA DMINISTRA TION INTRADERMAL WILFRIED FISCHER KATHARINASTOEGER 09/523.652
	26-Jun-01	1948733.9	OW		153656	ÓW		26-Jun-01	777		10-Mar-00	57
	2-Mar-05	1296650									24-Sep-02	6,455,066

	14-Aug-02 F ebruary 29, 2008		EPICEPT CORPORATION	301717-009015
255023	H/00 136 &	TOPICAL COMP ROBERT O. WILLIAMS FEN P A (a J 2004/00 136 8	EPICEPT CORPORATION	010071-0016-009
		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	
				Registered
				New Zealand
	14-Aug-02 December 14,2006		EPICEPT CORPORATION	301717-008015
531547	531547	TOPICAL COMPOSITION COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-008
		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	Q
				Australia Registered
18-Sep-08	14-Aug-02		EPICEPT CORPORATION	301717-007015
2002335635	2002335635	TOPICAL COMPOSITION COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-007
		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	
				Canada Registered
26-Oct-10	14-Aug-02		EPICEPT CORPORATION	301717-001015
2,457,780	2,457,780	TOPICAL COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-001
	W	ILENE B. TANNEN PETER G. THURLOW	Attomeys:	Compress
				Patent Cooperation Treaty Completed
	26-Jun-01	JOHN J. KOLENG GAVRIL W. PASTERNAK YURJ A. KOLESNIKOV	EPICEPT CORPORATION	301717-228009
	20322	METHODS AND COMPOSITION  S FOR TREATING THE FENGZHANG MUCOUSMIEMB  MUCOUSMIEMB  METHODS AND ROBERT O. WILLIAMS PCTIUSOI:20322	EPICEPT CORPORATION	010071-0010-228
	W	ILENE B. TANNEN PETER G. THURLOW	Attomeys:	

		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	Registered
10-Jun-09	14-Aug-02		EPICEPT CORPORATION	301717-146015 <b>China</b>
	2820112.4 ZL02820112.4	TOPICAL  COMPOSITION  S AND  ROBERT O. WILLIAMS  METHODS FOR FENGZHANG  TREATING  PAIN	EPICEPT CORPORATION	010071-0016-146
		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	Pending
	14-Aug-02		EPICEPT CORPORATION	301717-036015 Argentina
		TOPICAL  COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-036
		ILENE B. TANNEN PETER G. THURLOW	Attomeys	C
	15-Aug-02		EPICEPT CORPORATION	301717-025015 Venezuela Pending
		TOPICAL COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-025
		ILENE B. TANNEN PETER G. THURLOW	Attomeys:	
				Registered
2-1 00-10	17-248-02		ELICEL I COM ORGINON	Hong Kong
5 Feb 10	6109763 HKI089364	TOPICAL COMP ROBERT O. WILLIAMS FENI	EPICEPT CORPORATION	010071-0016-023
		ILENE B. TANKEM PETER G. THURLOW	Attomeys:	
				Registered
911	12 VIOS 02			Chile
8-Jul-09	12-Aug-02		EPICEPT CORPORATION	301717-010015
45.5		TOPICAL COMP ROBERT O. WILLIAMS FEN: 1813-2002	EPICEPT CORPORATION	010071-0016-010
	ETER G. THURLOW	ILENE B. TANNEN THOMAS E. FRIEBEL PETER G. THURLOW	Attomeys	vegarei en
				Registered

	JRLOW CELEMORRIS	ILENE B. TANNEN PETER G. THURLOW CELEMORRIS	Attomeys:	
				Patent Cooperation Treaty Completed
	1/-02-02		EFICEF I CONFORMITOIN	301/1/-22001/
	17 Oct 03	WOUND FAIN	EDICEDE CODADO ATION	201717 228017
	PCT1US02/33195	PAUL MASON	EPICEPT CORPORATION	010071-0018-228
	URLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:	
				Registered
F0-00100	T ) _ T M B O T		PITOLI I COM OMILION	United States of America
78 Oct 03	17 A::7 01		EDICEDE CODADA ATION	201717 000015
6,638,981	91.931.293	TOPICAL COMPOSITION S AND ROBERT O. WILLIAMS METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-999
	SRLOW CELEMORRIS	ILENE B. TANNEN PETEK G. THUKLOW CELEMOKKIS	Attomeys:	
				Completed
				Patent Cooperation Treaty
	14-Aug-02		EPICEPT CORPORATION	301717-228015
	PCT:US02/25871	TOPICAL COMPOSITION S AND S AND S AND METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-228
	JRLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys	Pending
				European Patent Office
	14-Aug-02		EPICEPT CORPORATION	301717-227015
	2770398.2	TOPICAL COMPOSITION S AND S AND S AND METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0016-227
	THURLOW	ILENE B. TANNEN PETER G. THURLOW	Attomeys:	
				Registered
				Israel
160388	160388 May 18.2010	TOPICAL COMPROBERTO, WILLIAMS FEN	EPICEPT CORPORATION  EPICEPT CORPORATION	301717-158015
160388	160388		EPICEPT CORPORATION	010071-0016-158

	Japan Pending	301717-012050 EPICEPT CORPORATION	010071-0048-012 EPICEPT CORPORATION		United States of America Registered	301717-999027 EPICEPT CORPORATION	010071-0028-999 EPICEPT CORPORATION	Registered	301717-999026 EPICEPT CORPORATION United States of America	010071-0027-999 EPICEPT CORPORATION	Registered Attorneys:	United States of America	301717-999025	010071-0026-999 EPICEPT CORPORATION
Attomeys:		RPORATION		Attomeys:				Attomeys:	RPORATION					
ILENE B. TANNEN PETER G. THURLOW		JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. KOLESNIKOV	METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE TREATING MUCOUS MEMBRANE TROBERT O. WILLIAMS 2008-163375	ILENE B. TANNEN PETER G. THURLOW		FLORES OF KETAMINE OINTMENT May 30,1997	PROCESS FOR THE PREPARATION KENTON L. CROWLEY 08/866,770 JOHN A.	ILENE B. TANNEN PETER G. THURLOW		INTRADERMAL. PENETRATION AGENTS FOR TOPICAL WILFRIED FISCHER PETRA LOCAL HIJBER PAUL MASON AMESTHETICA DMINISTRA TION	ILENE B. TANNEN ILENE B. TANNEN		JOHN J. KOLENG GAVRIL W. PASTERNAK YURJ A. KOLESNIKOV	S FOR TREATING PAIN OF THE MUCOUSMEMB  RANE  ROBERT O. WILLIAMS FENGZHANG
		23-Jun-08				6-Oct-98	5,817,699		I0-Mar-00 8-Jun-04	6,746,689			17-Jun-02 21-Jan-03	101,172,455 6,509,028

	ILENE B. TANNEN PETER G. THURLOW	ILEN	Attomeys:	
				Pending
				Mexico
	October 19,2007		EPICEPT CORPORATION	301717-009054
	ROBERT O. WILLIAMS  PAla 12007/013047  FENGZHANG	TOPICAL COMPOSITION S AND ROBERT O. W METHODS FOR FENGZHANG TREATING PAIN	EPICEPT CORPORATION	010071-0053-009
	ILENE B. TANNEN PETER G. THURLOW	ILEN	Attomeys:	
25-Jan-00	8-Jul-99		rica EPICEPT CORPORATION	United States of America Registered
6,017,961	09:350,062	KETAMINE AND N-B U TYI P-AMINOBEZO ATE (Sic) IN PLO	EPICEPT CORPORATION	010071-0051-999
	ILENE B. TANNEN PETER G. THURLOW	ILEN	Attomeys:	
				Hong Kong Filed Wait Exam
	JOHN J. KOLENG GAVRIL W. PASTERNAK YURI A. 28-Feb-05 KOLESNIKOV	)}} M OI	EPICEPT CORPORATION	301717-023050
	ROBERT O. WILLIAMS FENGZHANG 5110883.4	METHODS AND COMPOSITION S FOR TREATING PAIN OF THE MUCOUS MEMBRANE	EPICEPT CORPORATION	010071-0048-023

# EXHIBIT C

Trademarks

[See Attached]

 $\label{eq:maximpharmaceuticals} {\tt INC./EPICEPT\ CORPORATION} \\ {\tt TRADEMARK\ STATUS\ REPORTS}$ 

Updated: April 26, 2011

MAXIM PHARMACEUTICALS, INC.- U.S. TRADEMARK APPLICATION REGISTRATIONS:

	CEPLENE 157T	(MAXIM	REF. NO.	MARK KMOB
the treatment of cancer	5: Pharmaceuticals, namely, compositions for	IM)	VO.	OLASS: GOODS/SERVICES
0.000	for 76/138212		APP.DATE	3S APP.NO./
7/12/2005	2967403		REG. DATE	REG. NO./
Renewal due 07112115	REGISTER ED		COMMEN TS	STATUS/

		_	1	ı	
CEPLENE	CEPLENE	CEPLENE	CEPLENE	CEPLENE	MARK
Iceland	European Community	China	Canada	Australia	COUNTRY
157WIS	157WEU	157WCN	157WCA	157WAU	KMOB REF. NO. (MAXIM)
5: Pharmaceuticals	or: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	5: Pharmaceuticals, namely compositions for the treatment of cancer	5: Pharmaceuticals, namely, compositions for the treatment of cancer and infectious diseases	CLASS: GOODS/SERVICES
2516/2003 10/6/2003	1965656 111122/00	2001045526 3/28/2001	1078344 10/12/2000	858297 11123/00	APP.NO./ APP.DATE
30/2004 01102/04	1965656 OS/22/02	1760656 5/7/2002	TMA687350 5/9/2007	858297 5/17/2001	REG. NO./ REG. DATE
REGISTER ED Renewal due 01102/14	REGISTER ED Renewal due 11122/20	REGISTER ED Renewal due 05/07/12	REGISTER ED Renewal due 05/09/22	REGISTER ED Renewal due 11123/20	STATUS/ COMMEN TS

$\Psi$
1
Ň
N
[]
7
IJ
Ŧ
$\simeq$
7
Ą
Έ
][
Л
Ή
$\Box$
2
٢.
,
INC
$\leq$
( )
F
Ŧ
0
Ř
H
G
Z
N TRA
Ŕ
Α
D
ET)
$\leq$
A
NDEMARK
$^{\sim}$
R
Æ
õ
E,
1/4AXIM PHARMACEUTICALS, INC FOREIGN TRADEMARK REGISTRATIO
IJ.
5
Π
ĭ
$\cong$
NS
-1

	VOITIV	Ceptens	
	156T		221T
the treatment of cancer and infectious diseases	5: Pharmaceuticals, namely, compositions for	the treatment of cancer	5: Pharmaceuticals, namely, compositions for
9/29/2000	76/138211	4/22/2010	85/021009
6/12/2007	3252103		
Section 8 & 15 due 06112114 Renewal due 06112117	REGISTER ED	NOA issued 11116/10 SOU/1 <sup>st</sup> due 5/15/11	PENDING

		VITNOV			VITNOV			CEPLENE			CEPLENE				CEPLENE			CEPLENE					CEPLENE			CEPLENE
		Canada			Australia			Switzerland			Norway				New Zealand			Liechtenstein					Japan			Israel
		ada			ralia			rland		,	vay				ealand			nstein					an			le!
		156WCA			156WAU			157WCH			157WNO				157WNZ			157WLI					157WJP			157WIL
and viral hepatitis	compositions for the treatment of cancer	5: Pharmaceuticals, namely	and infectious diseases	compositions for the treatment of cancer	5: Pharmaceuticals, namely,	and infectious diseases	treatment of cancer	5: Pharmaceuticals, namely, compositions for the		preparations	5: Pharmaceutical	and infectious diseases		compositions for the treatment of cancer	5: Pharmaceuticals, namely,			5: Pharmaceuticals	pharmaceuticals	infectious disease; other	pharmaceuticals for treatment of	Composed	5: Composed pharmaceuticals for treatment of cancer	and infections diseases	nearment of cancer	5: Pharmaceuticals, namely, compositions for the
10/12/2000		ely 1078345	11 1 22/00		858080	11 1 23/00		13973/2000	10107/03		200309400	9/29/2000			627694	10/8/2003		13015			3/30/2001		2001-029763	11126/00		144206
2000		345	2/00		080	3/00		/2000	7/03		9400	2000			594	2003		115			2001		29763	6/00		206
10/30108		TMA727471	5/17/2001		858080	4/4/2001		483420	9/1/2004		224104	5/24/2001			627694	01113/04		13015			5/16/2003		4671668	2/5/2002		144206
0108		27471	2001		080	2001		420	2004		104	2001			694	3/04		)15			2003		1668	2002		206
due 10/30/23	Renewal	REGISTER FD	due 11122/20	Renewal	REGISTER ED	due 11123/20	Renewal	REGISTER ED	due 09/01114	ED Renewal	REGISTER	due 09/29117	Renewal		REGISTER ED	due 11126/21	ED Renewal	REGISTER			due 05/16/13	Denowal	REGISTER ED	due 11126/21	Renewal	REGISTER ED

To the best of our knowledge, the information contained in this Status Report is accurate. This Status Report to not to be used or relied upon for any purpose other than your general information. The Status Report contains confidential material and is protected by the attorned to the best of our knowledge, the information contained in this Status Report is accurate. This Status Report to not be used or relied upon for any purpose other than your general information. The Status Report contains confidential material and is protected by the attorned to the best of our knowledge, the information contained in this Status Report is accurate. 11 1 28254/PJP/0426 1 1 DISCLAIMER

	NOA issued 10/26/10					
	ABANDONED		4/8/2010	the treatment of cancer		
	PENDING - TO BE		85/009435	5: Pharmaceutic al preparation for	MAXIM.220T	CROLIBULIN
	UNFILED			5: Topical analgesics	Т100	AMIKET
	COMMENTS	REG. DATE	APP.DATE		REF. NO. (EPCPT*)	
	STATUS /	REG. <i>NO.1</i>	APP.NO.I	CLASS: GOODSISE RVICES	RMOB	MARK
					DEMARK APPLICATIONS	EPICEPT CORPORATION - U.S. TRADEMARK APPLICATIONS
due 11123/20	4/4/2001 d	11123/00	and infectious diseases			
REGISTER ED	483419 F	13972/2000	5: Pharmaceuticals, namely, compositions for the treatment of cancer	156WCH	Switzerland	AILNOA
due 08/31111	08/31101 d	03/26101	and infectious diseases			
REGISTER ED	4503151 F	2001-027100	5: Pharmaceuticals, namely, compositions for the treatment of cancer	156WJP	Japan	AILNOA
due 11122/20	5/23/2002 d	11 1 22/00	and infectious diseases			
	1		compositions for the treatment of cancer		Community	
REGISTER ED	1966977 F	1966977	5: Pharmaceuticals, namely,	156WEU	European	AILNOA
Renewal due <i>05/07/12</i>	5/7/2002 d	3/28/2001	and infectious diseases			
	_		compositions for the treatment of cancer			
REGISTER	1760655	2001045525	5: Pharmaceuticals,	156WCN	China	VITNOV

TRADEMARK REPORT
EPICEPT CORPORATION
Jones Day
April 26, 20 II

LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-007 Cam No. 301717-007014	Australia
EPICEPT CORPORATION		1039048 1039048 25-Jan-05 25-Jan-05	18 )5 Renewal Due January 25. 2015	Registered
5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS	AND PROPHYLACT	IC TREATMENT OF PAIN, INFLAN	MMATION, TRAUMA, WOUNDS, BURNS AND	
LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-001 Cam No. 301717-001014	Canada
EPICEPT CORPORATION		1,244,794 TMA725,845 25-Jan-05 10-Oct-08	)8 Renewal Due October 10, 2023	Registered
ADHESIVE PATCH IMPREGNATED WITH TOPICAL ANALGESIC	ANALGESIC			
ceplene.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0067-146 Cam No. 301717-146011	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
ceplene.com.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0068-146 Cam No. 301717-146066	China
EPICEPT CORPORATION		December 13,2007		Registered

Renewal Due December 13,2012

-	:	:		
ceplene.net.cn	App.No. App. Date	Reg. No. Reg. Date	Cam No. 301717-146069	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
ceplene.org.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0070-146 Cam No. 301717-146012	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
EPICEPT	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0054-146 Cam No. 301717-146063	China
EPICEPT CORPORATION	6432338 December 12, 2007	8 6432338 March 28,2010	Renewal Due March 27, 2020	Registered
5 PHARMACEUTICAL PREPARATIONS, NAMELY ANTICANCER AGENTS AND TOPICAL ANALGESICS	CANCER AGENTS AND TOP	VICAL ANALGESICS		
epicept in Chinese	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0076-146 Cam No. 301717-146076	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
EPICEPT IN CHINESE CHARACTERS	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0062-146 Cam No. 301717-146064	China
EPICEPT CORPORATION	6432337	7 6432337		Registered

5 PHARMACEUTICAL PREPARATIONS, NAMELY ANTICANCER AGENTS AND TOPICAL ANALGESICS

December 12, 2007 March 28,2010

Renewal Due March 27, 2020

epicept.net.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0065-146 Cam No. 301717-146009	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
epicept.org.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0066-146 Cam No. 301717-146010	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
Internet Keyword Registration for epiceptcorporation" "	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0064-146 Cam No. 301717-146001	China
EPICEPT CORPORATION		February 21. 2008	Renewal Due February 21, 2018	Registered
Internet Keyword Registration for CEPLENE	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0078-146 Cam No. 301717-146005	China
EPICEPT CORPORATION		December 14,2007	Renewal Due December 14,2017	Registered
Internet Keyword Registration for Epicept in Chinese	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0080-146 Cam No. 301717-146007	China
EPICEPT CORPORATION		December 14,2007	Renewal Due December 14,2017	Registered
Internet Keyword Registration for LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0079-146 Cam No. 301717-146006	China

Registered	6	076 4510076	4510076	EPICEPT CORPORATION
China	Docket No. 010071-0047-146 Cam No. 301717-146048	Reg. No. Reg. Date	App.No. App. Date	LIDOP AIN IN CHINESE CHARACTERS
Registered	7 Renewal Due December 13, 2012	13-Dec-07		EPICEPT CORPORATION
China	Docket No. 010071-0075-146 Cam No. 301717-146075	Reg. No. Reg. Date	App.No. App. Date	lidopain in Chinese
	TION, TRAUMA, WOUNDS, BURNS AND	:NT OF PAIN, INFLAMMAT	PROPHYLACTIC TREATMI	5 TOPICAL PATCH FOR USE IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS
Registered	5 8 Renewal Due July 27, 2018	1075 4510075 28-Jul-08	4510075 February 21,2005	EPICEPT CORPORATION
China	Docket No. 010071-0046-146 Cam No. 301717-146014	Reg. No. Reg. Date	App.No. App. Date	LIDOPAIN
Registered	Renewal Due December 14,2017	December 14,2007		EPICEPT CORPORATION
China	Docket No. 010071-0077-146 Cam No. 301717-146003	Reg. No. Reg. Date	App.No. App. Date	Internet Keyword Registrationn for EPICEPT
Registered	Renewal Due December 14,2017	December 14,2007		EPICEPT CORPORATION
China	Docket No. 010071-0081-146 Cam No. 301717-146008	Reg. No. Reg. Date	App.No. App. Date	Internet Keyword Registration for Lidopain in Chinese
Registered	Renewal Due December 14,2017	December 12,2007		EPICEPT CORPORATION

February 21,2005

7-Jul-08

Renewal Due July 6, 2018

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

lidopain.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0071-146 Cam No. 301717-146071	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
lidopain.com.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0072-146 Cam No. 301717-146072	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
lidopain.net.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0073-146 Cam No. 301717-146073	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
lidopain.org.cn	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0074-146 Cam No. 301717-146074	China
EPICEPT CORPORATION		December 13,2007	Renewal Due December 13,2012	Registered
LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-300 Cam No. 301717-300014	European Community

**EPICEPT CORPORATION** 

4256699 25-Jan-05

4256699 25-Jan-05

Registered

# Renewal Due January 25. 2015

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS

EPICEPT (STYLIZED)	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0009-003 Cam No. 301717-003008	Germany
EPICEPT GMBH	3998. 28-I	39982506.1 39982506 28-Dec-99 12-Apr-00	5 ) Renewal Due December 31, 2019	Registered
5 PHARMACEUTICAL PREPARATIONS, NAMELY TOPICAL ANALGESICS	AL ANALGESICS			
LIDOPAIN	App. No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-023 Cam No. 301717-023014	Hong Kong
EPICEPT CORPORATION	3003 February 1,2005	300364653 2005 February 1,2005	3 Renewal Due January 31, 2015	Registered
5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS	) PROPHYLACTIC TR	EATMENT OF PAIN, INFLAM	MATION, TRAUMA, WOUNDS, BURNS AND	
LIDOPAIN IN CHINESE CHARACTERS	App. No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0047-023 Cam No. 301717-023048	Hong Kong
EPICEPT CORPORATION	30037 February 28,2005	300377442 300377442 3,2005 February 28,2005	2 Renewal Due February 27, 2015	Registered
5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS	) PROPHYLACTIC TR	EATMENT OF PAIN, INFLAM	MATION, TRAUMA, WOUNDS, BURNS AND	
LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-056 Cam No. 301717-056014	India

INFECTIONS

1348025 30-Mar-05

1348025

30-Mar-05

Registered

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND Renewal Due March 30, 2015

		EPICEPT CORPORATION		LIDOPAIN	
	28-J	2005-6730	App. Date	App.No.	
	28-Jan-05 8	4	Reg. Date	Reg. No.	
Renewal Due September 8, 2016	8-Sep-06	4985525	Cam No. 301717-012014	Docket No. 010071-0046-012	
		Registered		Japan	

5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, BURNS AND INFECTIONS, AND OTHER PHARMACEUTICAL PREPARATIONS

LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-009 Cam No. 301717-009014	Mexico
EPICEPT CORPORATION	71	701065 87	876244	Registered
	February 9,2005	April 18,2005		
			Renewal Due February 9, 2015	
5 TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMATION, TRAUMA, WOUNDS, BURNS AND	AND PROPHYLACTIC TRI	EATMENT OF PAIN, INFI	LAMATION, TRAUMA, WOUNDS, BURNS AND	
INFECTIONS				
EPICEPT	App.No.	Reg. No.	Docket No. 010071-0054-999	United States of America
	App. Date	Reg. Date	Cam No. 301717-999056	

Section 8 & 15 Deadline July 17, 2013
Renewal Due July 17, 2017

5 PHARMACEUTICAL PREPARATIONS, NAMELY TOPICAL ANALGESICS

**EPICEPT CORPORATION** 

78/972,569 September 12.2006

3,265,139 17-Jul-07

Registered

LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0015-999 Cam No. 301717-999014	United States of America
EPICEPT CORPORATION	74/467,358	1, 8-Dec-93 1	1,906,291 18-Jul-95 Renewal Due July 18,2015	Registered
5 ADHESIVE PATCH IMPREGNATED WITH TOPICAL ANALGESIC	AL ANALGESIC			
LIDOPAIN	App.No. App. Date	Reg. No. Reg. Date	Docket No. 010071-0046-999 Cam No. 301717-999052	United States of America

5 MEDICATED TOPICAL PATCH FOR USE IN THE THERAPEUTIC AND PROPHYLACTIC TREATMENT OF PAIN, INFLAMMATION, TRAUMA, WOUNDS, **BURNS AND INFECTIONS** 

**EPICEPT CORPORATION** 

78/567,710

3,366,649 8-Jan-08

Registered

Renewal Due January 8, 2018

Section 8 & 15 Deadline January 8, 2014

15-Feb-05

# EXHIBIT D

Mask Works

None.

TRADEMARK REEL: 005593 FRAME: 0154

**RECORDED: 08/05/2015**